Compounding with Biotechnology Products, Part 1: General Considerations.

Area of Science:

• Biotechnology
• Pharmaceutical Sciences
• Pharmacology

Background:

• Biotechnology drugs are manufactured using living organisms and advanced techniques like recombinant DNA and monoclonal antibody technologies.
• These pharmaceuticals are vital for disease diagnosis, treatment, and prevention.
• The potential for adverse effects necessitates enhanced safety surveillance.

Purpose of the Study:

• To highlight the critical role of pharmacists in monitoring and reporting adverse events associated with biotechnology drugs.
• To emphasize the importance of pharmacist knowledge in compounding and preparing these complex medications.
• To underscore the need for maintaining drug stability and biologic activity from preparation to patient administration.

Main Methods:

• Review of biotechnology drug production techniques, including recombinant DNA and monoclonal antibody technologies.
• Discussion of the risks and safety surveillance requirements for biotechnology-derived pharmaceuticals.
• Exploration of the pharmacist's role in drug compounding, storage, preparation, and administration.

Main Results:

• Biotechnology drugs, initially proteins, are expanding to include smaller molecules, broadening pharmaceutical research.
• Pharmacists must understand both the active biotechnology agent and its excipients for safe compounding.
• Maintaining sterility and biologic activity is crucial throughout the preparation and administration process.

Conclusions:

• Pharmacists are essential in the safety monitoring and adverse event reporting for biotechnology drugs.
• Expertise in compounding, storage, and administration by pharmacists ensures patient safety and therapeutic efficacy.
• Continued pharmacist education is vital for managing the evolving landscape of biotechnology pharmaceuticals.